Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
This comparison focuses on four compounds that define the current state of the field: semaglutide (the established benchmark), tirzepatide (the dual-agonist leader), retatrutide (the triple-agonist frontier), and orforglipron (the oral non-peptide breakthrough)
Melanotan-2 has no FDA approval)
Diuretic medications: amiloride (Midamor), triamterene (Dyrenium), spironolactone (Aldactone), etc
Tirzepatide has a shorter half-life of about five days
The characteristics of the compound are displayed in Extended Data Fig
US$ 26.97
US$ 23.48
US$ 24.74
US$ 28.10
